Healing the Patient of Tomorrow
Products on well-understood commercialization tracks often take an incremental approach rather than trying to create paradigm-shifting technologies. In this blog, I’ll take a look at medical devices that are on a commercialization track to heal the patient of tomorrow in a way that is substantially better than previous offerings. They are generally broken into three broad categories based on their advantages over existing medical devices: either healing the patient at home, fixing issues with existing devices, or creating non-invasive diagnostic tools. Connected Home Use Devices Connected home-use devices allow a patient to undergo most of their recovery or treatment at home. This increases opportunities for rest and connects unedited patient data directly to the physician rather than getting a version of the story from the patient. In most cases, patients receive more physician attention than they would from visiting clinics periodically. The medical practitioner has information access on an instant feedback loop even when the patient is at home. Home-use therapy that connects directly to healthcare providers is a fantastic example of modern therapeutics and has been explored a number of times in digital health resources. Don't miss New England's largest event for medtech professionals! Get 20% off registration for the BIOMEDevice Boston Conference with promo code "MDDI". Patients using these devices can take part in their own care, where appropriate. Usage a...
Conclusion: This paper addresses the clinical implications of performing numerous CT examinations in patients with cancer, providing clinicians with information regarding methods to reduce risk factors in this patient population.Blood Purif 2018;46:56 –69
Conclusions: RDLs are frequently observed in high-risk patients for gastric cancer after eradication. M-NBI demonstrated significantly superior diagnostic efficacy with respect to RDL.Digestion 2018;98:48 –55
Conclusion: EVs and PHG exacerbation may predict PHE exacerbation in patients with LC.Digestion 2018;98:33 –40
This study showed that ESE-16 exposure leads to the aggregation of acidic vesicles, identified as lysosomes, not accompanied by an induction of autophagy. Therefore, ESE-16 disrupts normal endocytic vesicle maturation likely through the inhibition of the microtubule function.Pharmacology 2018;102:9 –16
Preclinical and clinical studies have shown that viral-based immunotherapy has the potential to overcome resistance to immune checkpoint blockade (ICB) and to fill the unmet needs of many cancer patients. Poxviruses, such as modified vaccinia virus Ankara (MVA), have the potential as cancer immunotherapeutic agents. We recently showed that intratumoral (IT) delivery of inactivated modified vaccinia virus Ankara (iMVA) induces antitumor systemic immunity via the STING-mediated cytosolic DNA-sensing pathway and Batf3 –dependent CD103+/CD8+ dendritic cells (DCs).
MicroRNA-155 (miR-155) has recently been shown to regulate anti-tumor immune responses. However, its specific functions within distinct immune cell types during this process have not been delineated utilizing conditional knockout mouse models. In recently published work, we discovered a role for miR-155 expression within the T cell compartment during the immune response to syngeneic B16f10 mouse melanoma tumors. We found that miR-155 expression within T cells is required to limit syngeneic tumor growth and promote interferon gamma (IFN γ) production within the tumor microenvironment.
In this study, we investigated the role of Bregs in tumor immunity. We used B cell-specific phosphatase and tensin homolog (PTEN)-deficient mice and B16F10 melanoma cells, which were subcutaneously injected into mice.
Patients with high-frequency non-syndromic basal cell carcinomas (BCCs) have not been systematically studied in the US due to lack of national registries. Previous studies have focused on risk factors for developing multiple BCCs, defined as ≥2 BCCs, but few have evaluated patients with high-frequency BCCs. This retrospective study of a commercially insured US population within the Truven MarketScan database from 2012-2015 defines high-frequency BCCs (non-basal cell nevus syndrome (BCNS)) as developing 12-19 BCCs within 4 years.
Skin cancer is one of the most preventable forms of cancer. Roughly, 85% of skin cancer cases could be avoided by reducing UV exposure, especially during adolescence. We conducted a pilot study to evaluate sun safety behaviors in this age group, as well as, the effects of an innovative intervention in changing sun protection attitudes and behaviours. Methods: Participants were recruited from 8 secondary schools in Vancouver, BC. Participants were segregated into the control arm (N=38) or intervention arm (N=138).
Annabelle Y. Guo, PhD1, Indra Neil Sarkar, PhD1,3, Elizabeth S. Chen, PhD1,3,Joanna Walker, MD2, Paul Stey, PhD3, Wen Qing Li, PhD2, Eunyoung Cho, ScD2, Abrar A. Qureshi, MD21The Warren Alpert Medical School; 2Department of Dermatology; 3Center for Biomedical Informatics, Brown University, Providence, RI. Merkel Cell Carcinoma (MCC) is an aggressive malignant skin cancer with a high mortality rate. The effect of ultraviolet (UV) exposure on MCC patients long-term survival is not fully understood.